DOTA-(Tyr3)-octreotate can be obtained through preparation of DOTA-containing peptides and radionucleotide complexes as antitumor agents for treating somatostatin postive tumor and metastasized tumors.
CAT No: R1831
CAS No:177943-89-4
Synonyms/Alias:177943-89-4;DOTA-(Tyr3)-Octreotate acetate;L-Lysine-1,2,3,4,5,6-13C6-N2,N6-15N2, Hydrochloride; (S)-2,6-Diaminohexanoic acid-13C6,15N2 hydrochloride; 13C and 15N Labeled Lys; 13C and 15N Labeled Lysine Hydrochloride; SILAC Amino Acid;;MFCD09039058;EX-A9168;G13545;
1. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy
2. TMEM16F and dynamins control expansive plasma membrane reservoirs
4. Cell-based adhesion assays for isolation of snake venom’s integrin antagonists
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.